The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
Michael John NissenBénédicte DelcoigneDaniela di GiuseppeLennart T H JacobssonMerete Lund HetlandAdrian CiureaLucie NekvindovaFlorenzo IannoneNurullah AkkocTuulikki Sokka-IslerKaren Minde FagerliMaria Jose SantosCatalin CodreanuManuel Pombo-SuarezZiga RotarBjorn GudbjornssonIrene van der Horst-BruinsmaAnne Gitte LoftBurkhard MöllerHerman MannFabrizio ContiGozde Yildirim CetinHeikki RelasBrigitte MichelsenPedro Avila RibeiroRuxandra IonescuCarlos Sanchez-PiedraMatija TomsicÁrni Jón GeirssonJohan AsklingBente GlintborgUlf LindströmPublished in: Rheumatology (Oxford, England) (2022)
This large European study of axial SpA patients showed similar one-year treatment outcomes for TNFi monotherapy and csDMARD co-therapy, although considerable heterogeneity across countries limited the identification of certain subgroups (e.g. peripheral arthritis) that may benefit from co-therapy.